Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Jul 23;1(9):916-924.
doi: 10.34067/KID.0000462020. eCollection 2020 Sep 24.

Patency Outcomes of Arteriovenous Fistulas and Grafts for Hemodialysis Access: A Trade-Off between Nonmaturation and Long-Term Complications

Bram M Voorzaat  1 , Cynthia J Janmaat  2 , Koen E A van der Bogt  3   4 , Friedo W Dekker  2 , Joris I Rotmans  1
Affiliations
Multicenter Study

Patency Outcomes of Arteriovenous Fistulas and Grafts for Hemodialysis Access: A Trade-Off between Nonmaturation and Long-Term Complications

Bram M Voorzaat et al. Kidney360. .

Abstract

Background: Arteriovenous fistulas (AVFs) for hemodialysis (HD) are often associated with better outcomes than arteriovenous grafts (AVGs). We aimed to investigate vascular access (VA) outcomes and assessed if AVF nonmaturation outweighs long-term complications of AVGs.

Methods: In this multicenter, retrospective cohort study in The Netherlands, 1- and 3-year primary, primary assisted, secondary, and functional patency rates were calculated, and the incidence of adverse events and procedures was assessed. Functional patency of RCAVFs, upper arm AVFs, and AVGs was compared using Cox analyses.

Results: In total, 1041 patients who received their first VA were included, of whom 863 had VAs that successfully matured. These patients were analyzed with a median follow-up of 25 months. The 1-year functional patency rates were 67%±2.0% for RCAVFs, 83%±2.0% for upper arm AVFs, and 85%±3.5% for AVGs. Three-year functional patency rates were 62%±2.0% for RCAVFs, 74%±2.0% for upper arm AVFs, and 69%±5% for AVGs. AVGs required more procedures per year (3.3 per year) of functional patency when compared with upper arm AVFs (1.8 per year).

Conclusions: The functional patency of AVFs and AVGs is comparable, although AVGs required more interventions to maintain usability for HD. The choice of VA is a trade-off between short-term advantages, favoring AVGs, and long-term advantages, favoring AVFs. Which VA is most appropriate depends on the patient's prognosis and preferences.

Keywords: arteriovenous fistula; arteriovenous graft; dialysis; patency; vascular access.

PubMed Disclaimer

Conflict of interest statement

All authors have nothing to disclose.

Figures

None
Graphical abstract
Figure 1.
Figure 1.
Visual example of patency measures. VA, vascular access.
Figure 2.
Figure 2.
Flowchart of inclusion and exclusion from analysis. AVF, arteriovenous fistula; AVG, arteriovenous graft; RCAVF, radiocephalic arteriovenous fistula.
Figure 3.
Figure 3.
Postcannulation primary patency of RCAVF that matured with and without interventional procedures, excluding RCAVFs that never matured.
Figure 4.
Figure 4.
Primary, primary assisted, secondary, and functional patency for RCAVFs, upper arm AVFs, and AVGs. Patients are censored for death and transplantation. (A–D) Clinical outcomes of all VAs, excluding VAs that did not mature (n=863). (E–H) Clinical outcomes of all VAs, including nonmatured VAs (n=1041).
Figure 5.
Figure 5.
Postintervention primary patency of RCAVF after subsequent procedures. Postintervention patency starts at the index procedure and ends at the next procedure, occlusion, or abandonment of the VA, and patients are censored for death and transplantation.
See this image and copyright information in PMC

References

    1. Tordoir J, Canaud B, Haage P, Konner K, Basci A, Fouque D, Kooman J, Martin-Malo A, Pedrini L, Pizzarelli F, Tattersall J, Vennegoor M, Wanner C, Wee Pt, et al. R: EBPG on vascular access. Nephrol Dial Transplant 22[Suppl 2]: ii88–ii117, 2007 - PubMed
    1. Schmidli J, Widmer MK, Basile C, de Donato G, Gallieni M, Gibbons CP, Haage P, Hamilton G, Hedin U, Kamper L, Lazarides MK, Lindsey B, Mestres G, Pegoraro M, Roy J, Setacci C, Shemesh D, Tordoir JHM, van Loon M, Kolh P, de Borst GJ, Chakfe N, Debus S, Hinchliffe R, Kakkos S, Koncar I, Lindholt J, Naylor R, Vega de Ceniga M, Vermassen F, Verzini F, Mohaupt M, Ricco JB, Roca-Tey R; ESVS Guidelines Committee; ESVS Guidelines Reviewers : Editor’s choice—vascular access: 2018 Clinical practice guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 55: 757–818, 2018 - PubMed
    1. Rothuizen TC, Wong C, Quax PHA, van Zonneveld AJ, Rabelink TJ, Rotmans JI: Arteriovenous access failure: More than just intimal hyperplasia? Nephrol Dial Transplant 28: 1085–1092, 2013 - PubMed
    1. Lok CE, Sontrop JM, Tomlinson G, Rajan D, Cattral M, Oreopoulos G, Harris J, Moist L: Cumulative patency of contemporary fistulas versus grafts (2000-2010). Clin J Am Soc Nephrol 8: 810–818, 2013 - PMC - PubMed
    1. Pisoni RL, Young EW, Dykstra DM, Greenwood RN, Hecking E, Gillespie B, Wolfe RA, Goodkin DA, Held PJ: Vascular access use in Europe and the United States: Results from the DOPPS. Kidney Int 61: 305–316, 2002 - PubMed

Publication types

MeSH terms